The Third Unit, The Department of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Front Endocrinol (Lausanne). 2023 Jun 22;14:1199429. doi: 10.3389/fendo.2023.1199429. eCollection 2023.
The MBOAT7 rs641738 (C>T) variant has demonstrated an association with non-alcoholic fatty liver disease (NAFLD) in both adult and pediatric patients, while few studies have been conducted in elderly populations. Hence, a case-control study was undertaken to assess their correlation in elderly residents in a Beijing community.
A total of 1,287 participants were included. Medical history, abdominal ultrasound, and laboratory tests were recorded. Liver fat content and fibrosis stage were detected by Fibroscan. Genotyping of genomic DNA was performed using the 96.96 genotyping integrated fluidics circuit.
Of the recruited subjects, 638 subjects (56.60%) had NAFLD, and 398 subjects (35.28%) had atherosclerotic cardiovascular disease (ASCVD). T allele carriage was associated with higher ALT (p=0.005) and significant fibrosis in male NAFLD patients (p=0.005) compared to CC genotype. TT genotype was associated with reduced risk of metabolic syndrome (OR=0.589, 95%CI: 0.114-0.683, p=0.005) and type 2 diabetes (OR=0.804, 95%CI: 0.277-0.296, p=0.048) in NAFLD population when compared to the CC genotype. In addition, TT genotype was also associated with reduced risk of ASCVD (OR=0.570, 95%CI:0.340-0.953, p=0.032) and less obesity (OR=0.545, 95%CI: 0.346-0.856, p=0.008) in the whole population.
MBOAT7 rs641738 (C>T) variant was associated with fibrosis in male NAFLD patients. The variant also reduced risk of metabolic traits and type 2 diabetes in NAFLD and ASCVD risk in Chinese elders.
MBOAT7 rs641738（C>T）变异与成人和儿科患者的非酒精性脂肪性肝病（NAFLD）相关，而在老年人群中进行的研究较少。因此，进行了一项病例对照研究，以评估该变异在北京社区老年居民中的相关性。
共纳入 1287 名参与者。记录了病史、腹部超声和实验室检查结果。使用 Fibroscan 检测肝脏脂肪含量和纤维化分期。使用 96.96 基因分型集成流体电路对基因组 DNA 进行基因分型。
在纳入的受试者中，638 名（56.60%）患有非酒精性脂肪性肝病，398 名（35.28%）患有动脉粥样硬化性心血管疾病（ASCVD）。与 CC 基因型相比，T 等位基因携带与男性 NAFLD 患者的 ALT 升高（p=0.005）和显著纤维化相关（p=0.005）。与 CC 基因型相比，TT 基因型与代谢综合征（OR=0.589，95%CI：0.114-0.683，p=0.005）和 2 型糖尿病（OR=0.804，95%CI：0.277-0.296，p=0.048）的风险降低相关在 NAFLD 人群中。此外，与 CC 基因型相比，TT 基因型还与 ASCVD（OR=0.570，95%CI：0.340-0.953，p=0.032）和肥胖（OR=0.545，95%CI：0.346-0.856，p=0.008）的风险降低相关。
MBOAT7 rs641738（C>T）变异与男性 NAFLD 患者的纤维化相关。该变异还降低了 NAFLD 和 ASCVD 风险人群中代谢特征和 2 型糖尿病的风险。
